PE20230382A1 - Nueva composicion farmaceutica para administracion de farmacos - Google Patents
Nueva composicion farmaceutica para administracion de farmacosInfo
- Publication number
- PE20230382A1 PE20230382A1 PE2022002543A PE2022002543A PE20230382A1 PE 20230382 A1 PE20230382 A1 PE 20230382A1 PE 2022002543 A PE2022002543 A PE 2022002543A PE 2022002543 A PE2022002543 A PE 2022002543A PE 20230382 A1 PE20230382 A1 PE 20230382A1
- Authority
- PE
- Peru
- Prior art keywords
- pharmaceutical composition
- drug administration
- new pharmaceutical
- pharmaceutically acceptable
- composition
- Prior art date
Links
- 238000001647 drug administration Methods 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 3
- 239000000463 material Substances 0.000 abstract 2
- 239000012876 carrier material Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 150000002016 disaccharides Chemical class 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 239000000843 powder Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4515—Non condensed piperidines, e.g. piperocaine having a butyrophenone group in position 1, e.g. haloperidol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/095—Oxytocins; Vasopressins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Otolaryngology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Dispersion Chemistry (AREA)
- Pulmonology (AREA)
- Psychiatry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Una composicion farmaceuticamente aceptable, tal composicion esta en la forma de un polvo secado por aspersion que comprende una mezcla de: (a) una cantidad de dosis farmacologicamente efectiva de al menos un compuesto farmacologicamente activo; y (b) un material portador farmaceuticamente aceptable, tal material portador comprende una combinacion de un disacarido y un material polimerico.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB2007306.0A GB202007306D0 (en) | 2020-05-18 | 2020-05-18 | New pharmaceutical composition |
GBGB2009905.7A GB202009905D0 (en) | 2020-06-29 | 2020-06-29 | New pharmaceutical composition |
GBGB2018901.5A GB202018901D0 (en) | 2020-12-01 | 2020-12-01 | New pharmaceutical composition |
PCT/GB2021/051191 WO2021234366A1 (en) | 2020-05-18 | 2021-05-18 | New pharmaceutical composition for drug delivery |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20230382A1 true PE20230382A1 (es) | 2023-03-06 |
Family
ID=76138084
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2022002543A PE20230382A1 (es) | 2020-05-18 | 2021-05-18 | Nueva composicion farmaceutica para administracion de farmacos |
Country Status (24)
Country | Link |
---|---|
US (2) | US11737980B2 (es) |
EP (2) | EP4154866A1 (es) |
JP (1) | JP2023526098A (es) |
KR (1) | KR20230012502A (es) |
CN (1) | CN115666513A (es) |
AU (1) | AU2021276611A1 (es) |
BR (1) | BR112022023307A2 (es) |
CA (1) | CA3178769A1 (es) |
CL (1) | CL2022002979A1 (es) |
CO (1) | CO2022015183A2 (es) |
DK (1) | DK3962455T3 (es) |
ES (1) | ES2929818T3 (es) |
HR (1) | HRP20221361T1 (es) |
HU (1) | HUE060573T2 (es) |
IL (1) | IL297658A (es) |
LT (1) | LT3962455T (es) |
MD (1) | MD3962455T2 (es) |
MX (1) | MX2022014216A (es) |
PE (1) | PE20230382A1 (es) |
PL (1) | PL3962455T3 (es) |
PT (1) | PT3962455T (es) |
RS (1) | RS63725B1 (es) |
SI (1) | SI3962455T1 (es) |
WO (1) | WO2021234366A1 (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR127780A1 (es) * | 2021-11-25 | 2024-02-28 | Orexo Ab | Nueva composición farmacéutica que comprende adrenalina |
GB202117016D0 (en) * | 2021-11-25 | 2022-01-12 | Orexo Ab | New pharmaceutical device |
WO2023094818A1 (en) * | 2021-11-25 | 2023-06-01 | Orexo Ab | Pharmaceutical composition comprising biopharmaceutical drug compounds |
WO2023187393A1 (en) | 2022-03-31 | 2023-10-05 | Hovione Scientia Limited | Inhalation composite and carrier based formulation combination |
WO2023209662A1 (en) * | 2022-04-29 | 2023-11-02 | Pentide Therapeutics Limited | Pharmaceutical compositions of semaglutide and the methods of use thereof |
WO2024031148A1 (en) * | 2022-08-11 | 2024-02-15 | De Motu Cordis Pty Ltd | Inhalable epinephrine formulation |
Family Cites Families (114)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE759520A (fr) | 1969-11-28 | 1971-04-30 | Aspro Nicholas Ltd | Compositions d'aspirine |
US5082669A (en) | 1989-07-20 | 1992-01-21 | Dainippon Pharmaceutical Co., Ltd. | Rapid-releasing oral particle pharmaceutical preparation with unpleasant taste masked |
SE8904296D0 (sv) | 1989-12-21 | 1989-12-21 | Pharmacia Ab | Transdermal system |
NZ270049A (en) | 1993-12-06 | 1995-10-26 | Takeda Chemical Industries Ltd | Composition comprising a water insoluble or slightly water soluble compound and a cyclodextrin-carboxylic acid |
CH689139A5 (de) | 1995-04-03 | 1998-10-30 | Cerbios Pharma Sa | Verfahren zur Herstellung einer liposomalen, in Wasser dispergierbaren, oral zu verabreichenden, festen, trockenen therapeutischen Formulierung. |
DE19518810A1 (de) | 1995-05-26 | 1996-11-28 | Bayer Ag | Nasal-Applikator |
JP4462761B2 (ja) | 1998-03-10 | 2010-05-12 | バルワー エス.アー. | 格納容器に格納された液体製品を投与する装置、及び格納容器の充填方法 |
EP1637154A3 (en) * | 1998-07-08 | 2007-08-15 | Kirin-Amgen Inc. | High molecular weight medicine-containing preparation in powder form for administration through mucosa |
JP2000178184A (ja) | 1998-12-17 | 2000-06-27 | Lion Corp | 粒状組成物、錠剤及び粒状組成物の製造方法 |
GB9908921D0 (en) | 1999-04-19 | 1999-06-16 | Britannia Pharmaceuticals Ltd | Spray dispenser for opiod antagonists |
US6264981B1 (en) | 1999-10-27 | 2001-07-24 | Anesta Corporation | Oral transmucosal drug dosage using solid solution |
GB0003782D0 (en) | 2000-02-17 | 2000-04-05 | Dumex Ltd As | Process |
US6316029B1 (en) | 2000-05-18 | 2001-11-13 | Flak Pharma International, Ltd. | Rapidly disintegrating solid oral dosage form |
KR20010107754A (ko) | 2000-05-26 | 2001-12-07 | 민경윤 | 경구투여용 속용정의 제조 방법 |
FR2817847B1 (fr) | 2000-12-08 | 2003-03-28 | Tebro | Dispositif de distribution de produit fluide ou pulverulent |
IN192750B (es) | 2000-12-15 | 2004-05-15 | Ranbaxy Lab Ltd | |
LU90825B1 (en) | 2001-09-06 | 2003-03-07 | Iee Sarl | Method for the determination of one or more parameters of a seat passenger |
ITMI20012174A1 (it) | 2001-10-18 | 2003-04-18 | Univ Parma | Polvere per somministrazione nasale di farmaci |
FR2834212B1 (fr) | 2001-12-27 | 2004-07-09 | Besins Int Belgique | Utilisation d'une poudre a liberation immediate dans des compositions pharmaceutiques et nutraceutiques |
GB0201367D0 (en) | 2002-01-22 | 2002-03-13 | Ml Lab Plc | Composition |
AU2006207868A1 (en) | 2002-03-20 | 2006-09-28 | Alkermes, Inc. | Method and apparatus for producing dry particles |
CA2488976C (en) | 2002-06-28 | 2009-08-25 | Advanced Inhalation Research, Inc. | Inhalable epinephrine |
WO2004054511A2 (en) | 2002-12-13 | 2004-07-01 | The Regents Of The University Of California | Analgesic combination comprising nalbuphine |
JP5475215B2 (ja) | 2003-02-24 | 2014-04-16 | ファーマシューティカル プロダクションズ, インコーポレイテッド | 経粘膜薬物送達システム |
US20060115529A1 (en) | 2003-05-07 | 2006-06-01 | Seonghoon Jeong | Fast-melting tablets having taste-masking and sustained release properties |
US7749533B2 (en) | 2003-05-07 | 2010-07-06 | Akina, Inc. | Highly plastic granules for making fast melting tablets |
WO2004112702A2 (en) | 2003-06-13 | 2004-12-29 | Advanced Inhalation Research, Inc. | Low dose pharmaceutical powders for inhalation |
CN100471497C (zh) | 2003-06-25 | 2009-03-25 | 中国人民解放军军事医学科学院毒物药物研究所 | 盐酸纳洛酮鼻粉剂 |
TWI288649B (en) | 2003-10-09 | 2007-10-21 | Bioactis Ltd | Powdery medicine dispensing device for nasal cavity |
WO2005044186A2 (en) | 2003-10-28 | 2005-05-19 | Glaxo Group Limited | Inhalable pharmaceutical formulations employing desiccating agents and methods of administering the same |
CN1640402A (zh) | 2004-01-02 | 2005-07-20 | 广东奇方药业有限公司 | 一种稳定的纳洛酮粉针剂 |
IL159729A0 (en) | 2004-01-06 | 2004-06-20 | Doron I Friedman | Non-aqueous composition for oral delivery of insoluble bioactive agents |
US8642079B2 (en) | 2004-02-23 | 2014-02-04 | Hormos Medical Corporation | Solid formulations of ospemifene |
US9895444B2 (en) | 2004-08-25 | 2018-02-20 | Aegis Therapeutics, Llc | Compositions for drug administration |
CN1615867A (zh) | 2004-10-22 | 2005-05-18 | 北京阳光润禾科技有限公司 | 注射用盐酸纳洛酮冻干粉针制剂 |
CN1781479B (zh) | 2004-12-02 | 2010-06-30 | 和记黄埔医药企业有限公司 | 一种马蔺子素分散体系及其制备方法 |
CN101132769A (zh) | 2005-02-10 | 2008-02-27 | 奥瑞克索股份公司 | 用于药物的跨黏膜给药的药物组合物 |
KR101233235B1 (ko) | 2005-08-26 | 2013-02-15 | 에스케이케미칼주식회사 | 초기 용출율이 개선된 프란루카스트 고체분산체의 약제학적조성물 및 그의 제조방법 |
US20070202163A1 (en) | 2005-09-09 | 2007-08-30 | Mutasem Rawas-Qalaji | Fast-disintegrating epinephrine tablets for buccal or sublingual administration |
CN1939358A (zh) | 2005-09-30 | 2007-04-04 | 江西本草天工科技有限责任公司 | 肿节风分散片 |
CN1813739A (zh) | 2005-11-25 | 2006-08-09 | 王颖 | 一种注射用盐酸纳美芬冻干粉针制剂 |
WO2007086039A1 (en) | 2006-01-27 | 2007-08-02 | The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth, Near Dublin | A method of producing porous microparticles |
WO2007096906A2 (en) | 2006-02-27 | 2007-08-30 | Panacea Biotec Ltd. | Novel buccoadhesive compositions and process of preparation thereof |
WO2007108010A2 (en) | 2006-03-21 | 2007-09-27 | Jubilant Organosys Limited | Taste masked pharmaceutical composition for oral solid dosage form and process for preparing the same using magnesium aluminium silicate |
US20090208576A1 (en) | 2006-03-31 | 2009-08-20 | Gandhi Anilkumar S | Orally Disintegrating Tablets |
US20100034888A1 (en) | 2006-09-15 | 2010-02-11 | Hubert Clemens Pellikaan | Granulate containing a pharmaceutically active substance and method for its manufacture |
US20080269347A1 (en) | 2006-09-28 | 2008-10-30 | Azopharma, Inc. | Epinephrine formulations |
ES2435197T3 (es) | 2007-01-10 | 2013-12-16 | Board Of Regents, The University Of Texas System | Administración mejorada de composiciones de fármacos inmunosupresores para la administración por vía pulmonar |
WO2009040595A1 (en) | 2007-09-28 | 2009-04-02 | Wockhardt Research Centre | Multi-dose pharmaceutical composition of analgesic for nasal administration |
CN102083467B (zh) | 2008-03-11 | 2013-12-25 | Aska制药株式会社 | 固体分散体及其药物组合物、以及它们的制备方法 |
US20090246256A1 (en) | 2008-03-27 | 2009-10-01 | Al-Ghananeem Abeer M | Compositions and Methods for Transmucosal Delivery of Lofexidine |
US20090264530A1 (en) | 2008-04-16 | 2009-10-22 | Nickell Robert P | Combined nsaid and acetaminophen formulation and method |
US8715715B2 (en) | 2008-11-03 | 2014-05-06 | Nal Pharmaceuticals Ltd. | Dosage form for insertion into the mouth |
EP2432502B1 (en) * | 2009-05-20 | 2018-01-03 | Aeras | Stable, spray dried, immunogenic, viral compositions |
PL3106149T3 (pl) * | 2009-05-29 | 2020-06-01 | Pearl Therapeutics, Inc. | Kompozycje do płucnego dostarczania długo-działających antagonistów muskarynowych i długo-działających agonistów receptora beta-2 adrenergicznego oraz powiązane sposoby i układy |
EP2266563A1 (en) | 2009-06-11 | 2010-12-29 | Charité-Universitätsmedizin Berlin (Charité) | Use of opioid receptor antagonists for acute treatment of paraphilic arousal states |
WO2010144865A2 (en) | 2009-06-12 | 2010-12-16 | Meritage Pharma, Inc. | Methods for treating gastrointestinal disorders |
WO2011013003A2 (en) | 2009-07-31 | 2011-02-03 | Shin Nippon Biomedical Laboratories, Ltd. | Intranasal granisetron and nasal applicator |
CA2775404C (en) | 2009-09-25 | 2017-01-03 | Dr. Reddy's Laboratories Limited | Formulations comprising triptan compounds |
US20120064157A1 (en) | 2010-08-27 | 2012-03-15 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition and administrations thereof |
JP5877201B2 (ja) * | 2010-08-30 | 2016-03-02 | パルマトリックス,インコーポレイテッド | 肺疾患を治療するための乾燥粉末製剤および方法 |
BR112013007276A2 (pt) | 2010-10-01 | 2016-06-14 | Cipla Ltd | composição farmacêutica, processo para preparar uma composição farmacêutica, uso da coposição farmacêutica e método para tratar sobrecarga crônica de ferro |
US20120282335A1 (en) | 2010-12-02 | 2012-11-08 | Aptalis Pharmatech Inc. | Rapidly dispersing granules, orally disintegrating tablets and methods |
ES2832973T3 (es) | 2011-02-18 | 2021-06-11 | Biolingus Ip Llc | Procedimiento para preparar productos que comprenden principios activos estabilizados y composiciones que comprenden los mismos |
CN107260672A (zh) | 2011-05-13 | 2017-10-20 | 欧洲凯尔特公司 | 包含纳洛酮的鼻内药物剂型 |
KR101772263B1 (ko) | 2012-05-11 | 2017-08-28 | 액티버스 파마 컴퍼니 리미티드 | 유기 화합물 나노분체, 그 제조 방법 및 현탁액 |
CA2876883C (en) * | 2012-06-15 | 2022-11-01 | Nova Southeastern University | Epinephrine nanoparticles, methods of fabrication thereof, and methods for use thereof for treatment of conditions responsive to epinephrine |
US9789071B2 (en) * | 2012-06-27 | 2017-10-17 | G2B Pharma, Inc. | Intranasal formulation of epinephrine for the treatment of anaphylaxis |
EP3248642B1 (en) | 2012-06-28 | 2020-04-08 | The Government of The United States of America as represented by The Secretary of The Department of Health and Human Services | Nasal dry powder delivery system for vaccines and other treatment agents |
FR3007992B1 (fr) | 2013-07-05 | 2018-01-26 | Aptar France Sas | Dispositif de distribution de produit fluide ou pulverulent. |
CA2923270A1 (en) | 2013-09-03 | 2015-03-12 | Shin Nippon Biomedical Laboratories Ltd. (Snbl) | Intranasal formulation for the treatment of cardiopulmonary resuscitation (cpr), cardiac life support (cls), anaphylaxis and/or anaphylactoid reactions |
EP2886107A1 (en) | 2013-12-17 | 2015-06-24 | ObsEva S.A. | Oral formulations of pyrrolydine derivatives |
WO2015095389A1 (en) | 2013-12-18 | 2015-06-25 | Aegis Therapeutics, Llc | Compositions for drug administration |
EP3082816B1 (en) | 2013-12-20 | 2019-03-20 | Indivior UK Limited | Intranasal naloxone compositions and methods of making and using same |
US9480644B2 (en) | 2014-03-14 | 2016-11-01 | Opiant Pharmaceuticals, Inc. | Nasal drug products and methods of their use |
US10085937B2 (en) | 2014-03-14 | 2018-10-02 | Adapt Pharma Limited | Nasal drug products and methods of their use |
CA2944075C (en) * | 2014-04-04 | 2022-06-28 | Lam Therapeutics, Inc. | An inhalable rapamycin formulation for treating age-related conditions |
US20190008759A1 (en) | 2014-07-03 | 2019-01-10 | Darren Rubin | Safer and more effective methods of transmucosal delivery for raising blood pressure and stimulating the body |
US11135155B2 (en) | 2014-07-08 | 2021-10-05 | Hikma Pharmaceuticals Usa Inc. | Liquid naloxone spray |
EP3174534A1 (en) | 2014-08-01 | 2017-06-07 | KRKA, d.d., Novo mesto | Pharmaceutical formulation comprising an opioid agonist and an opioid antagonist prepared by melt granulation using lipid esters |
CA2962531C (en) | 2014-10-08 | 2023-05-23 | Eratech S.R.L. | Composition comprising at least one dry powder obtained by spray drying to increase the stability of the formulation |
WO2016074800A1 (en) | 2014-11-14 | 2016-05-19 | Asoltech S.R.L. | Composition based on coq10 |
EP3025705B8 (en) | 2014-11-25 | 2018-11-28 | Sanofi Ilaç Sanayi ve Ticaret Anonim Sirketi | Stable ivabradine formulations |
CN104547220A (zh) | 2014-12-30 | 2015-04-29 | 陈宏� | 一种治疗儿童视觉疲劳的中药组合物及其制剂 |
US10166197B2 (en) | 2015-02-13 | 2019-01-01 | St. John's University | Sugar ester nanoparticle stabilizers |
PE20171334A1 (es) | 2015-02-17 | 2017-09-13 | Lilly Co Eli | Formulacion en polvo nasal para el tratamiento de hipoglicemia |
US20170189352A1 (en) | 2015-03-13 | 2017-07-06 | Par Pharmaceutical, Inc. | Epinephrine formulations |
US20180296679A1 (en) | 2015-04-08 | 2018-10-18 | Chang-Chun Ling | Pharmaceutical compositions of polyanionic and non-ionic cyclodextrin-based dendrimers and uses thereof |
WO2016179026A1 (en) | 2015-05-01 | 2016-11-10 | Civitas Therapeutics, Inc. | Zolmitriptan powders for pulmonary delivery |
US10039710B2 (en) | 2015-09-18 | 2018-08-07 | Insys Development Company, Inc. | Epinephrine spray formulations |
AU2017210319A1 (en) | 2016-01-20 | 2018-08-23 | Flurry Powders, Llc | Encapsulation of lipophilic ingredients in dispersible spray dried powders suitable for inhalation |
ITUB20161027A1 (it) * | 2016-02-24 | 2017-08-24 | Altergon Sa | Preparazioni farmaceutiche oromucosali ad elevata biodisponibilita’ a base di ciclodestrina e sucralosio |
CA3017825C (en) | 2016-03-16 | 2023-09-19 | Omegatri As | Powders and tablets comprising omega-3 fatty acid derivatives and methods for their production |
US20170312226A1 (en) | 2016-04-28 | 2017-11-02 | Ascent Pharmaceuticals, Inc. | Pharmaceutical dosage forms |
WO2017208209A1 (en) | 2016-06-03 | 2017-12-07 | M et P Pharma AG | Nasal pharmaceutical compositions with a porous excipient |
WO2017218918A1 (en) | 2016-06-17 | 2017-12-21 | Ys Pharmtech | Stabilization of epinephrine formulations |
MX2019001313A (es) | 2016-08-05 | 2019-09-26 | Shin Nippon Biomedical Laboratories Ltd | Composiciones farmaceuticas. |
AU2017336776A1 (en) | 2016-09-28 | 2019-03-21 | Chrono Therapeutics Inc. | Transdermal drug delivery device for delivering opioids |
WO2018064672A1 (en) | 2016-09-30 | 2018-04-05 | Opiant Pharmaceuticals, Inc. | Treatment with intranasal naloxone |
US20180092839A1 (en) | 2016-10-03 | 2018-04-05 | Lance L. Gooberman | Medicated spray for treatment of substance abuse, overdose, addiction and impulse control disorders |
US20190262263A1 (en) | 2016-11-09 | 2019-08-29 | Opiant Pharmaceuticals, Inc. | Compositions, devices and methods for the treatment of opioid-receptor-mediated conditions |
CN110139651A (zh) | 2016-11-18 | 2019-08-16 | 欧邦特制药公司 | 用于治疗阿片样物质过量的组合物和方法 |
WO2018148382A1 (en) | 2017-02-10 | 2018-08-16 | Mucodel Pharma Llc | Chemically stable compositions of a pharmaceutical active agent in a multi-chambered delivery system for mucosal delivery |
CN111050760A (zh) | 2017-04-17 | 2020-04-21 | 希克玛制药美国公司 | 肾上腺素喷雾制剂 |
EP3668490A4 (en) | 2017-08-20 | 2021-06-09 | Formulex Pharma Innovations Ltd. | DRY POWDER COMPOSITIONS FOR INTRANASAL ADMINISTRATION |
US20180193332A1 (en) | 2017-10-09 | 2018-07-12 | Adapt Pharma Operations Limited | Low-temperature stable opioid antagonist solutions |
WO2019139865A1 (en) | 2018-01-10 | 2019-07-18 | Insys Development Company. Inc. | Methods of stabilizing epinephrine |
JP6941224B2 (ja) | 2018-02-06 | 2021-09-29 | イージス セラピューティクス,エルエルシー | 疾患の処置のための鼻腔内エピネフリン製剤及び方法 |
WO2019182745A1 (en) | 2018-03-19 | 2019-09-26 | Bryn Pharma, LLC | Epinephrine spray formulations |
CA3102815A1 (en) | 2018-06-13 | 2019-12-19 | Hikma Pharmaceuticals Usa Inc. | Epinephrine spray formulations |
WO2020205663A1 (en) | 2019-03-29 | 2020-10-08 | The Regents Of The University Of California | Inhaled statins as bronchodilators to improve lung function in respiratory diseases |
US10729687B1 (en) | 2019-07-09 | 2020-08-04 | Orexo Ab | Pharmaceutical composition for nasal delivery |
US10653690B1 (en) | 2019-07-09 | 2020-05-19 | Orexo Ab | Pharmaceutical composition for nasal delivery |
US11400045B2 (en) | 2020-03-16 | 2022-08-02 | Nasus Pharma Ltd. | Treatment with powdered intranasal epinephrine |
-
2021
- 2021-05-18 RS RS20221016A patent/RS63725B1/sr unknown
- 2021-05-18 MD MDE20220282T patent/MD3962455T2/ro unknown
- 2021-05-18 HU HUE21728101A patent/HUE060573T2/hu unknown
- 2021-05-18 LT LTEPPCT/GB2021/051191T patent/LT3962455T/lt unknown
- 2021-05-18 BR BR112022023307A patent/BR112022023307A2/pt unknown
- 2021-05-18 KR KR1020227040261A patent/KR20230012502A/ko active Search and Examination
- 2021-05-18 DK DK21728101.3T patent/DK3962455T3/da active
- 2021-05-18 HR HRP20221361TT patent/HRP20221361T1/hr unknown
- 2021-05-18 CN CN202180036365.8A patent/CN115666513A/zh active Pending
- 2021-05-18 EP EP22191078.9A patent/EP4154866A1/en active Pending
- 2021-05-18 PE PE2022002543A patent/PE20230382A1/es unknown
- 2021-05-18 AU AU2021276611A patent/AU2021276611A1/en active Pending
- 2021-05-18 PT PT217281013T patent/PT3962455T/pt unknown
- 2021-05-18 JP JP2022570692A patent/JP2023526098A/ja active Pending
- 2021-05-18 WO PCT/GB2021/051191 patent/WO2021234366A1/en active Application Filing
- 2021-05-18 MX MX2022014216A patent/MX2022014216A/es unknown
- 2021-05-18 PL PL21728101.3T patent/PL3962455T3/pl unknown
- 2021-05-18 SI SI202130007T patent/SI3962455T1/sl unknown
- 2021-05-18 CA CA3178769A patent/CA3178769A1/en active Pending
- 2021-05-18 ES ES21728101T patent/ES2929818T3/es active Active
- 2021-05-18 EP EP21728101.3A patent/EP3962455B1/en active Active
- 2021-05-18 IL IL297658A patent/IL297658A/en unknown
- 2021-12-02 US US17/540,929 patent/US11737980B2/en active Active
-
2022
- 2022-10-25 CO CONC2022/0015183A patent/CO2022015183A2/es unknown
- 2022-10-26 CL CL2022002979A patent/CL2022002979A1/es unknown
-
2023
- 2023-06-30 US US18/345,770 patent/US20240024244A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CO2022015183A2 (es) | 2023-02-27 |
ES2929818T3 (es) | 2022-12-02 |
PT3962455T (pt) | 2022-10-13 |
AU2021276611A1 (en) | 2022-12-15 |
CA3178769A1 (en) | 2021-11-25 |
KR20230012502A (ko) | 2023-01-26 |
PL3962455T3 (pl) | 2023-01-16 |
US11737980B2 (en) | 2023-08-29 |
RS63725B1 (sr) | 2022-12-30 |
LT3962455T (lt) | 2022-10-25 |
JP2023526098A (ja) | 2023-06-20 |
SI3962455T1 (sl) | 2022-11-30 |
BR112022023307A2 (pt) | 2022-12-20 |
HRP20221361T1 (hr) | 2023-01-06 |
EP4154866A1 (en) | 2023-03-29 |
US20220087938A1 (en) | 2022-03-24 |
WO2021234366A1 (en) | 2021-11-25 |
CN115666513A (zh) | 2023-01-31 |
IL297658A (en) | 2022-12-01 |
DK3962455T3 (en) | 2022-10-24 |
US20240024244A1 (en) | 2024-01-25 |
EP3962455A1 (en) | 2022-03-09 |
EP3962455B1 (en) | 2022-08-31 |
HUE060573T2 (hu) | 2023-03-28 |
MX2022014216A (es) | 2022-12-07 |
MD3962455T2 (ro) | 2022-12-31 |
CL2022002979A1 (es) | 2023-05-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20230382A1 (es) | Nueva composicion farmaceutica para administracion de farmacos | |
UY27908A1 (es) | Formulaciones y formas de dosificación para la administración controlada de topiramato | |
AR110986A2 (es) | Composiciones de ecteinascidina, formulaciones liofilizadas, método de preparación y uso | |
AR088875A1 (es) | Forma de dosis farmaceutica oral a prueba de manipulacion | |
CO5640072A2 (es) | Composiciones farmaceuticas que comprenden atorvastatina fabricada sin granulacion | |
CL2022000033A1 (es) | Composición farmacéutica para suministro nasal | |
GB2596884A8 (en) | Pharmaceutical composition | |
AR017694A1 (es) | Una composicion para la administracion nasal de un farmaco para tratar la disfuncion erectil, el uso de dicha composicion en la fabricacion de unmedicamento, y un procedimiento para la preparacion de la composicion | |
ECSP088403A (es) | Formulacion farmaceutica de absorción oral y su método de administracion | |
AR018410A1 (es) | Uso de una composicion para la manufactura de un medicamento que se usa para la prevencion o tratamiento de un estado agudo de asma y/o asma intermitentey/o episodios de asma cronico y metodo para la prevencion o tratamiento de un estado agudo de asma y/o asma intermitente y/o episodios de asma cron | |
TW200500098A (en) | Methods and dosage forms for increasing solubility of drug compositions for controlled delivery | |
BRPI0512230A (pt) | método para minimizar a retenção de pó sobre superfìcies | |
ECSP034826A (es) | Método para fabricar una composición farmacéutica de dosis baja | |
PE20091672A1 (es) | Nueva dosificacion y formulacion | |
CO5700794A2 (es) | Conservantes antimicrobianos para lograr una formulacion de dosis multiples usando ciclodextrinas beta para formas de dosificacion liquidas | |
AR074062A1 (es) | Agonistas del receptor s1p para el tratamiento de la malaria cerebral y forma farmaceutica | |
AR046036A1 (es) | Composiciones de risedronato y metodos para su uso | |
MX2009006699A (es) | Composicion y metodo para preparar tabletas oralmente disgregantes que contienen una alta dosis de ingredientes farmaceuticamente activos. | |
AR075866A1 (es) | Una dosis de ave5026 para el tratamiento de tromboembolismo venoso en pacientes con deterioro renal severo. uso. composicion farmaceutica. | |
AR068560A1 (es) | Composiciones farmaceuticas que comprenden la combinacion de un agente antiinflamatorio no esteroide y un agente inhibidor de la xantino oxidasa utiles para el control y tratamiento de la gota artritis gotosa y enfermedades relacionadas | |
CR9324A (es) | Preparación farmacéutica para la anticoncepción oral | |
MX2022013103A (es) | Nueva composicion farmaceutica multiparticulada de tamsulosina y solifenacina. | |
AR118056A2 (es) | Formulaciones de inhibidor de histona desacetilasa en combinación con bendamustina y uso de las mismas | |
AR127780A1 (es) | Nueva composición farmacéutica que comprende adrenalina | |
UY27866A1 (es) | Métodos y modalidades de dosificación para aumentar la solubilidad de compuestos de droga para una administración controlada |